A detailed history of Bessemer Group Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 286,988 shares of FULC stock, worth $932,711. This represents 0.0% of its overall portfolio holdings.

Number of Shares
286,988
Previous 286,988 -0.0%
Holding current value
$932,711
Previous $1.78 Million 42.38%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$5.01 - $8.35 $6,382 - $10,637
1,274 Added 0.45%
286,988 $2.09 Million
Q1 2022

May 12, 2022

SELL
$9.96 - $23.65 $236,121 - $560,670
-23,707 Reduced 7.66%
285,714 $6.76 Million
Q4 2021

Jan 27, 2022

SELL
$14.0 - $28.44 $16,758 - $34,042
-1,197 Reduced 0.39%
309,421 $5.47 Million
Q3 2021

Nov 12, 2021

BUY
$7.28 - $30.97 $181,301 - $771,276
24,904 Added 8.72%
310,618 $8.76 Million
Q3 2019

Nov 07, 2019

BUY
$6.64 - $14.89 $1.9 Million - $4.25 Million
285,714 New
285,714 $1.9 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $169M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.